Mesoblast (MESO) Competitors

Axsome Therapeutics (NASDAQ:AXSM) and Mesoblast (NASDAQ:MESO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, community ranking, dividends, risk, institutional ownership, profitability and valuation.

Do analysts recommend AXSM or MESO?

Axsome Therapeutics currently has a consensus price target of $172.80, suggesting a potential upside of 59.88%. Mesoblast has a consensus price target of $18.00, suggesting a potential upside of 51.64%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	0 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	3.06
Mesoblast	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

Does the media prefer AXSM or MESO?

In the previous week, Axsome Therapeutics had 24 more articles in the media than Mesoblast. MarketBeat recorded 34 mentions for Axsome Therapeutics and 10 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.93 beat Axsome Therapeutics' score of 0.19 indicating that Mesoblast is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mesoblast	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders hold more shares of AXSM or MESO?

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 22.3% of Axsome Therapeutics shares are owned by insiders. Comparatively, 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has higher earnings & valuation, AXSM or MESO?

Mesoblast has lower revenue, but higher earnings than Axsome Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$432.16M	12.31	-$287.22M	-$5.77	-18.73
Mesoblast	$5.67M	267.50	-$87.96M	N/A	N/A

Is AXSM or MESO more profitable?

Mesoblast has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -74.47%. Mesoblast's return on equity of 0.00% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-74.47%	-223.51%	-39.88%
Mesoblast	N/A	N/A	N/A

Which has more risk and volatility, AXSM or MESO?

Axsome Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Mesoblast has a beta of 2.41, indicating that its share price is 141% more volatile than the S&P 500.

Does the MarketBeat Community favor AXSM or MESO?

Axsome Therapeutics received 74 more outperform votes than Mesoblast when rated by MarketBeat users. Likewise, 70.93% of users gave Axsome Therapeutics an outperform vote while only 70.41% of users gave Mesoblast an outperform vote.

Company	Underperform	Outperform
Axsome Therapeutics	Outperform Votes 488 70.93%	Underperform Votes 200 29.07%
Mesoblast	Outperform Votes 414 70.41%	Underperform Votes 174 29.59%

Summary

Axsome Therapeutics beats Mesoblast on 9 of the 16 factors compared between the two stocks.